Wampole ELISA II
The Wampole ELISA II
products comprise one of the broadest lines of ELISA tests in the
industry. Over 60 assays are available across a broad menu,
including autoimmune disease, bladder cancer, cardiac risk
assessment, enteric disease, infectious disease, STDs, and
osteoporosis.
These test kits are capable of being run in a manual,
semi-automated, or fully automated capacity with customized
instrumentation packages available to suit individual laboratory
needs.
The Wampole ELISA II assays come in breakaway, removable test
wells in a microplate format, with color-coded, ready-to-use
reagents.
Most assays use interchangeable substrate, stop solution, and
wash buffer. This uniformity of reagents allows for ease of
automation with microtiter processing systems.
With standard assay protocols for faster integration into the
busy laboratory, our Infectious Disease ELISA products provide
increased reliability and run-to-run consistency.
The NMP22 ELISA test is the first and only test for the
screening and monitoring of bladder cancer patients.
State-of-the-art monoclonal and monoclonal/polyclonal
antibody-based technology is available in the enteric disease line
of products.
Wampole ELISA II kits provide flexible testing, with simple
procedures, a broad menu, and confidence in the results.
SAVe Diluent™ for added confidence—only found in Wampole ELISA
II assays
Other advanced technology exclusive to Wampole ELISA II tests is
Wampole SAVe Diluent™, a sample addition verification system that
assures no well has been missed. By changing color from yellow to
purple, it is a visual place keeper when preparing manual assays
and a rapid verifier of proper instrument performance when running
automated platforms.